Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] death 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Late treatment -2% 1.02 [0.48-2.17] 14/182 13/178 -2% improvement All studies 46% 0.54 [0.08-3.85] 14/710 17/707 46% improvement 2 sotrovimab COVID-19 studies c19sv.com Jan 21, 2022 Tau​2 = 1.28, I​2 = 52.0%, p = 0.55 Effect extraction pre-specified Favors sotrovimab Favors control
Sotrovimab COVID-19 studies. Efficacy is variant dependent. In Vitro studies suggest lower efficacy for omicron. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape. Recently added: Self. Sotrovimab has been officially adopted for early treatment in 9 countries. Submit updates/corrections.
Dec 23
Late Self et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00751-9 (Peer Reviewed)
death, ↑2.0%, p=0.96
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Details   RCT with 182 sotrovimab patients and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility. TICO. NCT04501978.
Dec 21
Early Rockett et al., medRxiv, doi:10.1101/2021.12.18.21267628 (Preprint) Resistance conferring mutations in SARS-CoV-2 delta following sotrovimab infusion
Details   Retrospective 100 sotrovimab patients in Australia, 23 PCR+ more than 10 days post-infusion (68 with status unknown), showing rapid development of spike gene mutations that have been shown to confer high level resistance to sotrovimab in ..
Dec 20
In Vitro Sheward et al., bioRxiv, doi:10.1101/2021.12.19.473354 (Preprint) (In Vitro)
In Vitro
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Details   In Vitro study showing that omicron is substantially resistant to neutralization by monoclonal antibodies REGN10933, REGN10987, Ly-CoV016 and Ly-CoV555. S309 (the parent of Sotrovimab) had only 2-fold loss in potency.
Dec 17
In Vitro VanBlargan et al., bioRxiv, doi:10.1101/2021.12.15.472828 (Preprint) (In Vitro)
In Vitro
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
Details   In vitro study (Vero-TMPRSS2 and Vero-hACE2-TMPRSS2) showing complete loss of inhibitory activity for B.1.1.529 omicron with LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59, ~12-fold decrease for COV2-2196/COV2-2130, and minimal ch..
Dec 15
In Vitro Liu et al., bioRxiv, doi:10.1101/2021.12.14.472719 (Preprint) (In Vitro)
In Vitro
Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
Details   In vitro study (Vero-E6-TMPRSS2) showing 18 of 19 monoclonal antibodies were no longer effective or significantly impaired with B.1.1.529 omicron.
Dec 4
Early Gupta et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab466.701 (Peer Reviewed)
death, ↓88.9%, p=0.12
Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Details   RCT 1,057 outpatients, 529 treated with sotrovimab, showing significantly lower hospitalization and ICU admission with treatment. NCT04545060. The preprint [1] for this study appears to show different results: 10, 6, 2 for ICU, ventilati..
May 26
Early Gupta et al., NEJM, doi:10.1056/NEJMoa2107934 (news release 5/26/2021) (Preprint)
death, ↓66.6%, p=1.00
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Details   Interim results from the COMET-ICE trial showing significantly lower hospitalization with treatment. NCT04545060.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit